CA2774154A1 - Compositions and methods for improving immune responses to hiv vaccination - Google Patents

Compositions and methods for improving immune responses to hiv vaccination Download PDF

Info

Publication number
CA2774154A1
CA2774154A1 CA2774154A CA2774154A CA2774154A1 CA 2774154 A1 CA2774154 A1 CA 2774154A1 CA 2774154 A CA2774154 A CA 2774154A CA 2774154 A CA2774154 A CA 2774154A CA 2774154 A1 CA2774154 A1 CA 2774154A1
Authority
CA
Canada
Prior art keywords
hiv
composition
subtype
human
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2774154A
Other languages
English (en)
French (fr)
Inventor
James T. Tartaglia
Sanjay Gurunathan
Jerome H. Kim
Don Francis
Supachai Rerks-Ngarm
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MINISTRY OF PUBLIC HEALTH
GLOBAL SOLUTIONS FOR INFECTIOUS DISEASES
SANOFI PASTEUR Inc
Walter Reed Army Institute of Research
Original Assignee
MINISTRY OF PUBLIC HEALTH
GLOBAL SOLUTIONS FOR INFECTIOUS DISEASES
SANOFI PASTEUR Inc
Walter Reed Army Institute of Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MINISTRY OF PUBLIC HEALTH, GLOBAL SOLUTIONS FOR INFECTIOUS DISEASES, SANOFI PASTEUR Inc, Walter Reed Army Institute of Research filed Critical MINISTRY OF PUBLIC HEALTH
Publication of CA2774154A1 publication Critical patent/CA2774154A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CA2774154A 2009-09-17 2010-09-17 Compositions and methods for improving immune responses to hiv vaccination Abandoned CA2774154A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24352209P 2009-09-17 2009-09-17
US61/243,522 2009-09-17
PCT/US2010/049206 WO2011035082A1 (en) 2009-09-17 2010-09-17 Immunological compositions for hiv

Publications (1)

Publication Number Publication Date
CA2774154A1 true CA2774154A1 (en) 2011-03-24

Family

ID=43086913

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2774154A Abandoned CA2774154A1 (en) 2009-09-17 2010-09-17 Compositions and methods for improving immune responses to hiv vaccination

Country Status (6)

Country Link
US (1) US20120308593A1 (enExample)
EP (2) EP2477651A1 (enExample)
JP (3) JP2013505256A (enExample)
AU (1) AU2010295497B2 (enExample)
CA (1) CA2774154A1 (enExample)
WO (1) WO2011035082A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10040826B2 (en) 2011-07-05 2018-08-07 Duke University Human immunodeficiency virus type 1 (HIV-1) N-terminal deleted GP120 immunogens
EP2763699A4 (en) 2011-10-03 2015-05-20 Univ Duke VACCINE
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
JP6491095B2 (ja) 2012-09-12 2019-04-03 デューク ユニバーシティ 抗体進化免疫原
US10906941B2 (en) 2013-04-15 2021-02-02 Duke University Methods of inducing an immune response against HIV-1 using recombinant envelopes with improved coverage
WO2015160726A2 (en) * 2014-04-14 2015-10-22 Indiana University Research And Technology Corporation A generalizable assay for virus capsid assembly
CN113924114A (zh) 2019-05-22 2022-01-11 吉利德科学公司 Tlr7调节化合物和hiv疫苗的组合
AU2020384323A1 (en) 2019-11-14 2022-06-02 Aelix Therapeutics, S.L. Dosage regimens for vaccines

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001233063A1 (en) * 2000-01-31 2001-08-07 Aaron Diamond Aids Research Center Vaccination of hiv infected persons following highly active antiretroviral therapy
EP1278541A1 (en) * 2000-04-28 2003-01-29 The Government of The United States of America, as represented by The Department of Health and Human Services Improved immunogenicity using a combination of dna and vaccinia virus vector vaccines

Also Published As

Publication number Publication date
WO2011035082A1 (en) 2011-03-24
JP2018039832A (ja) 2018-03-15
EP2987500A1 (en) 2016-02-24
EP2477651A1 (en) 2012-07-25
JP2016074727A (ja) 2016-05-12
JP2013505256A (ja) 2013-02-14
US20120308593A1 (en) 2012-12-06
AU2010295497A1 (en) 2012-04-19
AU2010295497B2 (en) 2014-10-09
JP6619788B2 (ja) 2019-12-11

Similar Documents

Publication Publication Date Title
US20230009041A1 (en) Modified immunization vectors
AU709174B2 (en) Mixture of recombinant vaccinia vectors as polyenv vaccines for HIV
JP6619788B2 (ja) Ｈｉｖ用の免疫学的組成物
US20140377306A1 (en) Recombinant vaccine viruses expressing il-15 and methods of using the same
JP2011523553A (ja) ＰｒｆＡ＊変異株リステリアを含む組成物およびその使用法
CN112930394B (zh) 表达ii类主要组织相容性复合物的癌细胞疫苗和用于产生整合免疫应答的使用方法
JP2024505274A (ja) ワクチン接種中のｔ細胞プライミングの強化において使用されるウイルスコンストラクト
AU2019334676B2 (en) HERV-K-derived antigens as shared tumor antigens for anti-cancer vaccine
PT1921146E (pt) Vectores recombinantes baseados no vírus modificado de ankara (mva) como vacinas preventivas e terapêuticas contra a sida
US20170065710A1 (en) Immunological Compositions
WO2023077147A2 (en) T-cell vaccines for patients with reduced humoral immunity
AU2015200094A1 (en) Immunological compositions for HIV
HK1083454B (en) Recombinant vaccine viruses expressing il-15 and methods of using the same

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150831

FZDE Discontinued

Effective date: 20220104